Crystal Rock Capital Management Has $4.70 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Crystal Rock Capital Management lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 24.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,185 shares of the company's stock after buying an additional 2,180 shares during the quarter. IDEXX Laboratories comprises approximately 3.2% of Crystal Rock Capital Management's holdings, making the stock its 12th largest position. Crystal Rock Capital Management's holdings in IDEXX Laboratories were worth $4,697,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. PFG Advisors grew its position in IDEXX Laboratories by 39.0% during the first quarter. PFG Advisors now owns 10,375 shares of the company's stock worth $4,357,000 after buying an additional 2,910 shares in the last quarter. HighPoint Advisor Group LLC increased its holdings in IDEXX Laboratories by 64.9% in the 1st quarter. HighPoint Advisor Group LLC now owns 915 shares of the company's stock valued at $400,000 after buying an additional 360 shares during the period. Crestwood Advisors Group LLC acquired a new position in shares of IDEXX Laboratories in the 1st quarter valued at $348,000. GW&K Investment Management LLC lifted its holdings in shares of IDEXX Laboratories by 3.0% during the 1st quarter. GW&K Investment Management LLC now owns 35,496 shares of the company's stock worth $14,907,000 after acquiring an additional 1,049 shares during the period. Finally, Los Angeles Capital Management LLC boosted its position in shares of IDEXX Laboratories by 1,889.1% during the 1st quarter. Los Angeles Capital Management LLC now owns 20,150 shares of the company's stock valued at $8,462,000 after acquiring an additional 19,137 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Up 1.2%

Shares of IDXX stock traded up $6.42 on Tuesday, reaching $527.29. 45,408 shares of the stock were exchanged, compared to its average volume of 639,745. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.16 and a quick ratio of 0.81. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $549.52. The stock has a market cap of $42.40 billion, a PE ratio of 48.77, a P/E/G ratio of 3.74 and a beta of 1.54. The stock has a 50 day moving average price of $523.58 and a 200 day moving average price of $463.41.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. IDEXX Laboratories's revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.71 earnings per share. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of analyst reports. Morgan Stanley raised their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Wall Street Zen upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday, July 12th. Jefferies Financial Group assumed coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target on the stock. Leerink Partners increased their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Finally, Stifel Nicolaus boosted their target price on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the company a "hold" rating in a research note on Wednesday, July 2nd. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $560.33.

Insiders Place Their Bets

In other news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director owned 1,801 shares of the company's stock, valued at $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.